FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease Isabella Ciccone, MPH

Published Date: 21 Nov 2026

The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Three out of ten breast cancers detected between screenings, study finds

2.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

3.

Where Did This Very Painful Gluteal Mass Come From?

4.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

5.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot